Sistema de Salut de Catalunya
Institut Català de la Salut
[González-Barcala FJ] Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain. Respiratory Medicine, Universidad de Santiago de Compostela, Santiago de Compostela, Spain. [Muñoz-Gall X] Servei de Pneumologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. CIBER of Respiratory Diseases (CIBERes), Madrid, Spain. Departament de Biologia Cel•lular, Fisiologia i Immunologia, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Mariscal E, García A] GlaxoSmithKline, Madrid, Spain. [Yang S] GlaxoSmithKline, Collegeville, PA, USA. [van de Wetering G] Pharmerit International, Rotterdam, the Netherlands. [Izquierdo-Alonso JL] Medicine and Specialities Department, Universidad de Alcalá (Alcalá de Henares, Madrid), Hospital Universitario Guadalajara, Guadalajara, Spain
Vall d'Hebron Barcelona Hospital Campus
2022-06-09T08:21:22Z
2022-06-09T08:21:22Z
2021
Asma eosinofílica greu; Comparació indirecta del tractament; Mepolizumab
Severe eosinophilic asthma; Indirect treatment comparison; Mepolizumab
Asma eosinofílica severa; Comparación de tratamiento indirecto; Mepolizumab
Aim To analyse the cost-effectiveness of MEP with standard of care (SoC) versus other anti-IL-5 therapies approved for the treatment of severe eosinophilic asthma (SEA) patients, within the Spanish National Health System (NHS) perspective. Methods A Markov model with a 4-week cycle length was used to compare MEP with BEN and RES as therapies added to SoC in the management of SEA, in terms of cost per QALY gained and incremental cost-effectiveness ratio (ICER). Costs (€2019) were obtained from public sources, while utilities and transition probabilities were retrieved from literature, e.g. network meta-analysis. Continuation criteria for biological treatment and reduction of oral corticosteroids (OCS) was set at 50% minimum reduction of exacerbation rate. Adverse events related to chronic OCS use included diabetes, osteoporosis, cataracts, acute myocardial infarct, and peptic ulcer. The analysis was performed over a 5-year time horizon from the National Healthcare System (NHCS) perspective, with a yearly discount rate of 3% applied to both costs and QALYs. Probabilistic sensitivity analysis and univariate deterministic sensitivity analysis were performed to address uncertainty around the cost-effectiveness results. Results On top of SoC, the model indicates that MEP is dominant (lower cost, higher benefit) compared to BEN and RES: For BEN and RES, respectively, treatment with MEP had a point estimate of 0.076 and 0.075 additional QALYs, and savings of €3,173.47 and €7,772.95 per patient. The findings were robust to variation as estimated using sensitivity analysis. Conclusions MEP is a cost-effective treatment in comparison with BEN and RES added to SoC for patients with SEA in the Spanish setting.
This study was funded by GlaxoSmithKline [Study code: HO-19-19968].
Article
Published version
English
Cost-eficàcia; Hormones esteroides - Ús terapèutic; Eosinofília; CHEMICALS AND DRUGS::Hormones, Hormone Substitutes, and Hormone Antagonists::Hormones::Adrenal Cortex Hormones; Other subheadings::Other subheadings::/therapeutic use; HEALTH CARE::Health Care Economics and Organizations::Economics::Costs and Cost Analysis::Cost-Benefit Analysis; DISEASES::Hemic and Lymphatic Diseases::Hematologic Diseases::Leukocyte Disorders::Eosinophilia; COMPUESTOS QUÍMICOS Y DROGAS::hormonas, sustitutos de hormonas y antagonistas de hormonas::hormonas::hormonas de la corteza suprarrenal; Otros calificadores::Otros calificadores::/uso terapéutico; ATENCIÓN DE SALUD::economía y organizaciones para la atención de la salud::economía::costes y análisis de costes::análisis coste-beneficio; ENFERMEDADES::enfermedades hematológicas y linfáticas::enfermedades hematológicas::trastornos leucocitarios::eosinofilia
Taylor & Francis
Journal of Medical Economics;24(1)
https://doi.org/10.1080/13696998.2021.1941065
Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
Articles científics - HVH [3439]
